Revascularization of the ischemic canine hindlimb by arteriovenous reversal.
Arteriovenous reversal (AVR) for revascularization of ischemic tissues has previously failed to meet theoretical, experimental, and clinical expectations despite recurrent trials. The efficacy of a new staged approach to AVR was tested against a canine ischemic limb preparation in which global ligation of ipsilateral collaterals inevitably led to limb gangrene. In 12 animals the complications of direct, single-stage end-to-end femoral AVR, inevitably accompanied by the development of extreme edema, were demonstrated. However, when the ischemic preparation was accompanied by a staged AVR, in which an initial end-artery-to-side-vein arteriovenous fistula was converted 1 week later to AVR by ligation of the central venous limb, 20 of 20 animals survived, and 19 of 20 were ambulatory long-term survivors with only mild edema. Serial angiograms at 1 week, 1 month, and 4 months demonstrated patency rates of 100, 84, and 63%, respectively. Histologic examination of animals electively killed from 4 to 24 months showed normal skeletal muscle histology, venous intimal thickening, and mild edema. In the acutely ischemic canine hind limb, a staged AVR can provide both viability and function with only mild edema formation.
D000818:Animals; D001166:Arteriovenous Shunt, Surgical / Q000379:methods*; D003097:Collateral Circulation; D004285:Dogs; D005260:Female; D005263:Femoral Artery / Q000601:surgery*; D005268:Femoral Vein / Q000601:surgery*; D006614:Hindlimb / Q000098:blood supply; D007511:Ischemia / Q000209:etiology / Q000601:surgery*; D008297:Male